Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Apr 7, 2017; 23(13): 2355-2364
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2355
Table 1 Clinical features of the patients who achieved sustained virologic response 12 with DCV + ASV or SOF + LDV
Therapy regimenDCV + ASVSOF + LDVP value
Number121132
SVR 1285.8%97.7%
Gender (M:F)59:6249:830.075
mean ± SDmean ± SD
Age (yr)68.4 ± 11.866.7 ± 13.10.280
AST (IU/L)56.4 ± 39.651.7 ± 33.30.300
ALT (IU/L)51.9 ± 40.546.5 ± 38.30.270
Hb (g/dL)13.3 ± 1.713.3 ± 1.70.830
Plt (104/μL)13.9 ± 5.915.5 ± 7.0< 0.05
Alb (g/dL)3.9 ± 0.534.0 ± 0.45< 0.05
T-Bil (mg/dL)0.87 ± 0.570.76 ± 0.390.086
PT (%)88.6 ± 15.690.4 ± 13.70.330
TC (mg/dL)163.7 ± 33.3171.1 ± 34.90.087
TG (mg/dL)113.4 ± 83.0112 ± 58.90.870
LDL-C (mg/dL)82.8 ± 27.289.2 ± 28.50.068
HDL-C (mg/dL)55.5 ± 18.458.7 ± 17.60.160
HCV-RN A (log•IU/mL)5.9 ± 0.785.9 ± 0.870.960
Fib4 index4.9 ± 3.34.7 ± 4.00.640